Cerevance
Cerevance is a biotechnology company focused on developing treatments for central nervous system disorders, particularly neurodegenerative conditions like Alzheimer's, Parkinson's, and ALS, using its proprietary NETSseq platform and an extensive brain tissue database.
Company Overview
Cerevance focuses on developing treatments for central nervous system (CNS) disorders, particularly targeting neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis (ALS). The company applies advanced techniques including a proprietary NETSseq platform and machine learning to discover new gene expression profiles specific to certain cell types.
Proprietary NETSseq Platform
Cerevance leverages its proprietary NETSseq platform to identify novel gene expression profiles that are relevant to CNS diseases. This platform enables the identification of targets expressed in single cell types and those altered by disease conditions. The NETSseq platform has generated over 45 trillion base pairs sequenced and more than 100 terabytes of data, providing a unique and actionable picture of CNS diseases for precision therapy.
CNS Disorder Treatments
Cerevance has a portfolio of treatments in development targeting various CNS disorders. CVN424, a first-in-class non-dopamine therapy, aims to improve motor and non-motor symptoms in Parkinson's disease. CVN766 is an Orexin 1 receptor antagonist with potential benefits for conditions like schizophrenia and anxiety. CVN293 targets KCNK13 to reduce neuroinflammation and slow neurodegeneration in ALS and Alzheimer's disease. CVN293 is currently in Phase 1 trials for safety and tolerability, with results expected in Q2 2024.
Brain Tissue Database
With one of the world’s largest proprietary brain tissue databases, Cerevance has RNA deeply sequenced in approximately 60 human brain cell types. Their extensive collection of over 14,000 human brain tissue samples aids in generating a comprehensive catalog of promising targets for CNS disorder treatments. This resource is fundamental in advancing research and identifying potential drug targets and pathways most impacted in CNS diseases.
Research Collaborations
Cerevance has formed strategic alliances to enhance its research capabilities. Notably, it has a multi-year research alliance with Takeda Pharmaceutical Company Limited to discover novel CNS target proteins for new therapeutic developments in gastrointestinal disorders. Cerevance also collaborates with Merck to identify novel targets for Alzheimer's disease using its NETSseq technology platform.